See analyst estimates and all valuation multiples for Vaccines & Immunotherapies
| Company | EV | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| $220B | 3.4x | 8.1x | |
| $169B | 2.7x | 7.0x | |
| $130B | 2.7x | 9.2x | |
| $86.8B | 2.1x | 6.1x | |
| $83.2B | 5.5x | 16.4x | |
| $29.2B | 4.3x | 16.4x | |
| $11.1B | 27.4x | 84.6x | |
| $8.2B | 2.1x | 15.1x | |
| $5.5B | 12.5x | 41.1x | |
| $5.1B | 1.8x | -3.9x | |
| $4.8B | 5.8x | 21.8x | |
| $3.7B | 6.0x | 14.4x | |
| $3.3B | 1.1x | -0.9x | |
| $2.6B | 7.2x | 40.2x | |
| $2.5B | 62.5x | n/a | |
| $2.5B | n/a | n/a | |
| $2.4B | 5.8x | 19.1x | |
| $2.3B | n/a | n/a | |
| $1.8B | 4.5x | 21.8x | |
| $1.8B | 14.1x | -19.3x | |
| $1.5B | 5.9x | -25.8x | |
| $1.4B | 1.7x | 5.7x | |
| $1.2B | n/a | n/a | |
| $1.1B | n/a | n/a | |
| $1.1B | n/a | n/a | |
| $1.0B | 5.4x | 7.4x | |
| $956M | n/a | n/a | |
| $866M | n/a | n/a | |
| $827M | 5.6x | 11.8x | |
| $820M | 2.8x | 18.5x | |
| $675M | 2.8x | 9.9x | |
| $673M | 3.7x | n/a | |
| $666M | 15.2x | n/a | |
| $613M | n/a | n/a | |
| $605M | n/a | n/a | |
| $597M | 3.2x | 49.4x | |
| $592M | n/a | n/a | |
| $555M | n/a | n/a | |
| $496M | n/a | n/a | |
| $493M | 82.1x | -2.5x | |
| $478M | n/a | n/a | |
| $475M | 68.9x | -1.6x | |
| $449M | n/a | n/a | |
| $395M | 7.2x | -21.2x | |
| $385M | 5.2x | -15.1x | |
| $316M | 1.9x | 9.0x | |
| $305M | 77.6x | -17.0x | |
| $274M | 1.3x | -2.3x | |
| $272M | 0.4x | -2.0x | |
| $261M | 3.3x | -2.3x | |
| $240M | n/a | n/a | |
| $238M | n/a | n/a | |
| $223M | n/a | n/a | |
| $198M | 0.5x | 1.6x | |
| $191M | n/a | n/a | |
| $172M | 60.8x | n/a | |
| $170M | n/a | n/a | |
| $155M | 35.0x | -0.6x | |
| $148M | 21.0x | -9.7x | |
| $147M | 15061.3x | n/a | |
| $132M | n/a | n/a | |
| $127M | n/a | -3.6x | |
| $122M | 197.2x | -2.0x | |
| $115M | n/a | n/a | |
| $113M | 5798.3x | -0.4x | |
| $107M | 1.0x | n/a | |
| $106M | n/a | n/a | |
| $105M | n/a | n/a | |
| $105M | 1.4x | 2.7x | |
| $101M | 64.5x | -1.2x | |
| $100M | n/a | n/a | |
| $84.4M | n/a | n/a | |
| $74.9M | n/a | n/a | |
| $73.4M | 2.6x | n/a | |
| $70.6M | n/a | n/a | |
| $69.9M | 12501.7x | -2.9x | |
| $69.5M | n/a | n/a | |
| $68.8M | 3.7x | -2.8x | |
| $49.6M | 11.0x | n/a | |
| $44.3M | 2.1x | n/a | |
| $43.8M | 5.5x | n/a | |
| $43.6M | 1.6x | n/a | |
| $41.1M | n/a | n/a | |
| $39.8M | n/a | n/a | |
| $39.3M | 2342.3x | n/a | |
| $37.5M | 0.3x | -1.0x | |
| $29.2M | n/a | -0.8x | |
| $29.1M | n/a | n/a | |
| $28.9M | n/a | -1.3x | |
| $26.7M | 30.0x | n/a | |
| $25.6M | n/a | n/a | |
| $16.9M | 17.7x | n/a | |
| $7.3M | 2.0x | n/a | |
| $7.2M | 1.0x | -0.5x | |
| $6.9M | n/a | n/a | |
| $5.4M | 65.5x | -0.2x | |
| $2.4M | 1.1x | -0.0x | |
| -$1.5M | n/a | 0.0x | |
| -$1.6M | -0.1x | n/a | |
| -$2.6M | n/a | n/a | |
| -$2.8M | -2.7x | n/a | |
| -$5.8M | -1.1x | 0.5x | |
| -$6.9M | -0.1x | 0.1x | |
| -$7.4M | -0.4x | n/a | |
| -$8.2M | -0.4x | 0.2x | |
| -$8.7M | -1.4x | n/a | |
| -$9.2M | -1.0x | 0.8x | |
| -$16.1M | -0.1x | 0.2x | |
| -$18.4M | -19.9x | n/a | |
| -$29.5M | -0.8x | n/a | |
| -$32.0M | n/a | n/a | |
| -$32.5M | -8.1x | 0.4x | |
| -$32.7M | -32.3x | n/a | |
| -$34.2M | -0.4x | 0.3x | |
| -$37.6M | -4.6x | 0.8x | |
| -$38.7M | -0.3x | -1.7x | |
| -$46.4M | -2.0x | n/a | |
| -$52.6M | n/a | n/a | |
| -$53.2M | -0.9x | 0.1x | |
| -$58.6M | n/a | 0.5x | |
| -$62.2M | n/a | n/a | |
| -$65.7M | -14.3x | 0.4x | |
| -$66.6M | -6.2x | 0.4x | |
| -$69.2M | -6.6x | n/a | |
| -$72.8M | n/a | n/a | |
| -$84.0M | -0.4x | 0.3x | |
| -$84.7M | -0.7x | n/a | |
| -$88.5M | n/a | 0.8x | |
| -$89.8M | n/a | 0.8x | |
| -$92.5M | -52.6x | 0.7x | |
| -$101M | n/a | n/a | |
| -$111M | -27.4x | 0.9x | |
| -$116M | n/a | n/a | |
| -$117M | -664.4x | n/a | |
| -$146M | -1.0x | n/a | |
| -$155M | -8.5x | 0.7x | |
| -$184M | -4307.0x | 0.6x | |
| -$197M | n/a | 1.3x | |
| -$241M | -9.0x | 1.5x |
Valuation multiples as of last 12 months (LTM). Financial data powered by Morningstar, Inc.
See analyst estimates and M&A multiples for Vaccines & Immunotherapies